重组人生长激素对慢性重型肝炎患者的疗效观察

目的:探讨重组人生长激素(rhGH)治疗慢性重型肝炎患者的临床疗效。方法:将52例慢性重型肝炎患者分为2组,治疗组27例(rhGH每日4或4.5 IU2,～11周),对照组25例,比较2组的症状、生化指标及生存率。结果:治疗组临床症状改善总有效率明显高于对照组。生化指标显示:治疗4周后,治疗组前白蛋白(PALB)水平高于对照组,差异具有统计学意义。2组治疗后2周、4周、3个月6、个月1、年生存率比较,治疗组均明显高于对照组(P<0.05)。结论:rhGH可改善重型肝炎患者的症状及部分生化指标,并能提高慢性重型肝炎患者的生存率。

Efficacy of Human Growth Hormone Recombinant for Chronic Severe Hepatitis

OBJECTIVE： To evaluate the clinical efficacy of human growth hormone recombinant（rhGH） for chronic severe hepatitis.METHODS： A total of 52 patients with chronic severe hepatitis were assigned to either treatment group（rhGH at a dose of 4 or 4.5 IU·d-1 for 2-11 weeks） or control group,The symptoms,biochemical indicators and survival rate between the two groups were compared.RESULTS： The treatment group showed significantly better improvement in clinical symptoms than in the control group.In terms of the biochemical indicators after treatment of four weeks,the level of prealbumin（PALB） in treatment group was significantly higher than in the control group,with the differences showing statistical significance.At 2 weeks,4 weeks,3 months,6 months and 1 year,the survival rate in the treatment group was always significantly higher than in the control group（P0.05）.CONCLUSION： rhGH can improve the symptoms and part of biochemical indicators and the survival rate of patients with severe hepatitis.